Promising Data in CLL With Ibrutinib/Venetoclax Doublet

Findings from the phase 2 CAPTIVATE study demonstrate that the doublet of ibrutinib and venetoclax may be an attractive line of therapy for ...

5-Year CAPTIVATE Results Show Promise in CLL/SLL With Ibrutinib ...

Overall, these 5-year data show that patients can be retreated safely with either ibrutinib alone or given in combination with venetoclax after ...

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in ...

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL · New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL ...

Combinations or sequences of targeted agents in CLL: is the whole ...

Thus, facilitating apoptosis is a promising strategy. Venetoclax, an oral, bcl-2 inhibitor has impressive efficacy in R/R CLL. In a phase 1 dose-escalation ...

The Potential Role of Venetoclax Combination Approaches in CLL

I think the doublets also look very good with ibrutinib plus venetoclax, so we need more data with acalabrutinib plus venetoclax and ...

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and ...

Time-limited combination therapy, whether oral or in combination with IV antibodies, is a promising approach in CLL treatment with the aim of ...

Update on the management of relapsed/refractory chronic ... - Nature

Continuous covalent inhibitors of Bruton's tyrosine kinase (cBTKi) and fixed-duration venetoclax (Ven)-anti-CD20 monoclonal antibody (mAb) are ...

Ibrutinib plus Venetoclax: Are We Ready for This Combination in ...

The 4-year follow-up data showed that the rate of uMRD (<10-4 by multicolor flow cytometry) in the bone marrow (BM) was 52% and 64% after 12 and ...

First-line venetoclax combinations versus chemoimmunotherapy in ...

The MRD-guided triple combination of venetoclax–obinutuzumab–ibrutinib shows promising efficacy and yields longer progression-free survival in ...

Key highlights in CLL: clinical trial updates & the role of combination ...

The experts comment on the role of doublet therapies with ibrutinib and venetoclax, and discuss long-term follow-up data from several clinical trials.

An update on the efficacy of Venetoclax for chronic lymphocytic ...

The BCL2 inhibitor venetoclax has dramatically changed the treatment of chronic lymphocytic leukemia (CLL) and has introduced the concept of ...

Ibrutinib combinations in CLL therapy - blood cancer journal - Nature

Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently ...

Therapeutic targeting of apoptosis in chronic lymphocytic leukemia

Therapeutic targeting of apoptosis with small molecule B-cell lymphoma 2 (BCL-2) inhibition with venetoclax is highly efficacious in CLL, leading to sustained ...

Novel combination approaches with targeted agents in frontline ...

Multiple randomized trials have documented the efficacy of oral therapy with the Bruton tyrosine kinase inhibitors ibrutinib and acalabrutinib ( ...

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab ...

Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax (PV) or ...

Ibrutinib plus venetoclax show promise in treatment-naïve CLL - BJH

Results from a recent phase II study indicate that the bruton tyrosine kinase (BTK) inhibitor ibrutinib plus the BCL2 inhibitor venetoclax may be an ...

Current and future treatment strategies in chronic lymphocytic ...

A retrospective chart review found that BTK inhibitor therapy for patients with CLL who had disease progression following venetoclax treatment ...

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO ...

"We are encouraged by these data and the potentially potent combination of ibrutinib plus venetoclax treatment for CLL and potentially other ...

Management of CLL patients: BTK inhibition and beyond

Among the remaining patients, 84 % achieved uMRD with venetoclax plus ibrutinib. In total, MRD was achieved in 87 % with either the monotherapy or the ...

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic ...

30 In a phase 2 single-center trial of 80 previously untreated patients, 23% of whom had aberrated TP53, ibrutinib-venetoclax administered for 24 cycles ...